Beyond the standard blood draw: why Signatera is different
A standard blood panel can tell your care team a lot, but it can’t tell them whether microscopic traces of your specific tumor are still circulating in your body. Signatera can. And the way it does that is fundamentally different from any generic cancer blood test.
Liquid biopsy panels are designed to scan for genes that are frequently mutated across many patients with a given cancer type, selected based on analysis of large numbers of tumors that have already been sequenced. Signatera takes the opposite approach. It starts with your tumor tissue, a biopsy sample from surgery or a procedure, and sequences the DNA unique to your cancer. From that analysis, it builds a custom molecular fingerprint mapped specifically to you.
Bespoke vs. generic testing: A generic panel looks for mutations shared across a population. Signatera sequences your tumor first, then creates a personalized test designed to detect only your cancer’s DNA in a blood draw, making it far more precise for post-treatment monitoring.
That fingerprint becomes the target. Every subsequent blood draw is then analyzed to detect whether any fragments of that tumor-specific DNA, called circulating tumor DNA or ctDNA, are present in your bloodstream. Signatera is designed to identify DNA patterns unique to your cancer and create a personalized molecular profile based on your individual tumor. Your care team can explain how this approach may be used to monitor for cancer recurrence.
Understanding that distinction, bespoke design versus broad-panel screening, is the foundation for interpreting any result you receive. And the result that tends to raise the most questions is a positive one, which is where the concept of Molecular Residual Disease becomes essential.
Understanding a Signatera ‘Detected’ result: the MRD factor
A Signatera ‘Detected’ result means microscopic tumor DNA has been detected in your blood, not that your scans look alarming.
Molecular Residual Disease (MRD) is the clinical term for tiny fragments of tumor DNA circulating in your bloodstream that standard imaging simply can’t pick up. When Signatera returns a “Detected” result, it’s identifying these fragments using the personalized genetic fingerprint built from your own tumor tissue. Even if a CT scan shows nothing unusual, MRD can signal that cancer cells are still present at a level too small for conventional tools to see.
That’s why a positive result after surgery carries real weight. Data from the GALAXY study found that patients who remain ctDNA positive following surgery face roughly 10x the recurrence risk compared to those who clear circulating tumor DNA. It’s one of the most clinically significant statistics in colorectal cancer monitoring right now.
Many oncologists and researchers describe a positive result as a window of opportunity, a chance to act before a recurrence becomes visible or symptomatic. In practice, this might include accelerated imaging, a conversation with your care team about adjuvant therapy, or enrollment in a clinical trial. Your personalized care plan can be adjusted precisely because Signatera caught something early.
Understanding what a positive result means naturally raises the next question. What does Signatera ‘Not Detected’ mean, and does “Not Detected” mean you’re in the clear?
What a Signatera ‘Not Detected’ result means (and what it doesn’t)
Circulating tumor DNA (ctDNA) testing through a simple blood test can help doctors monitor for signs of colorectal cancer recurrence and answer important questions about whether cancer may return. Understanding what your ctDNA results mean is an important part of your follow-up care.
A negative Signatera result means your care team found no circulating tumor DNA in your blood at the time of testing. That’s a meaningful signal. Research shows that a negative ctDNA result carries a high negative predictive value, meaning the probability that recurrence is actually brewing undetected is low. According to the Colorectal Cancer Alliance, a negative result suggests a much lower risk of recurrence, and that’s reassuring context your care team can use when building your personalized care plan.
However, “Not Detected” is not the same as “zero risk.” Blood tests like Signatera may miss some colorectal cancers because of how the cancer forms in the gut. Once tumor DNA reaches the bloodstream, the cancer is often already more advanced, making early-stage cancers harder to detect through blood alone. In other cases, ctDNA levels may simply fall below the test’s current limit of detection. Both scenarios are uncommon, but they’re real, and they’re why a single negative result doesn’t function as a permanent guarantee.
Important note: Levels of circulating tumor DNA can occasionally fall below the limit of detection even in the presence of residual disease. A negative result should always be interpreted alongside your full clinical picture, including imaging and your care team’s assessment.
Think of each Signatera result as a high-resolution snapshot, not a final verdict. Ongoing surveillance, regular retesting at intervals your care team recommends, is what transforms individual data points into a reliable pattern over time. And as you’ll see in the next section, one of the most powerful reasons to keep testing is the timing advantage that early molecular detection can offer, often well before a scan would catch anything at all.
The lead-time advantage: beating the CT scan
Understanding the full Signatera results meaning requires knowing what makes ctDNA testing fundamentally different from the tools that came before it. Signatera can detect colorectal cancer recurrence 6–10 months earlier than standard imaging or CEA blood tests, according to research published in the Journal of Clinical Oncology. That lead time is a window your care team can act within.
Lead time refers to detecting cancer at the molecular level, before it has grown into a visible mass on a CT scan. When even a handful of tumor cells survive treatment and begin shedding DNA into your bloodstream, Signatera can identify those fragments. Conventional imaging like CT scans can only detect a tumor once it has grown to a certain size, which means disease may be growing for months before it shows up on these scans.
CEA vs. ctDNA is where the distinction becomes especially important. CEA (carcinoembryonic antigen) is a protein that can rise in the presence of colorectal cancer, but it’s nonspecific. Inflammation, smoking, and even benign gastrointestinal conditions can elevate CEA levels, triggering anxiety and additional testing that leads nowhere. Signatera creates a personalized panel based on mutations found in your tumor’s DNA, allowing it to detect cancer recurrence in your blood. Natera’s clinical data shows this specificity reduces the noise that can complicate post-treatment monitoring.
That 6–10 month head start matters most when it comes to your personalized care plan. Catching a potential recurrence earlier means your care team can consider systemic treatment options before the disease has spread widely, potentially changing what interventions are on the table and how effective they can be. Of course, a single result is only part of the picture, which is why tracking how your ctDNA levels shift over time tells an even more complete story.
Serial testing: why the trend matters more than the snapshot
A single ctDNA result tells part of the story, but it’s the pattern across multiple tests over time that gives your care team the clearest picture of what’s happening.
Longitudinal monitoring involves tracking how ctDNA levels change across serial blood draws over time, rather than relying on a single result. Your care team may discuss whether this pattern of results can help inform your follow-up care. Mayo Clinic oncologists generally recommend blood testing for carcinoembryonic antigen every three to six months during the first two years after treatment, then every six months for an additional three years as part of colorectal cancer surveillance.
Track how ctDNA levels change over time, not just individual results. Persistent ctDNA after treatment is associated with a markedly worse prognosis than ctDNA that clears with chemotherapy, suggesting that ongoing monitoring of your ctDNA status provides important information for predicting your risk of cancer recurrence. A consistent downward trajectory of ctDNA after chemotherapy (ctDNA clearance) is a meaningful positive signal.
Low-level positives still demand attention. A result like 0.5, technically above the detection threshold, may seem minor, but it warrants prompt follow-up. Per Natera’s clinical guidance, even low-level signals reflect real tumor-derived DNA circulating in your bloodstream. Your care team will typically respond by shortening the interval before your next draw or ordering confirmatory imaging to assess whether that signal is growing.
A recommended monitoring cadence during years one through three generally looks like this:
- Every three months: ctDNA blood draw during active surveillance
- Every six months: CT imaging (often coordinated with ctDNA results)
- Immediately: repeat testing or imaging if any draw returns a positive result
Understanding this rhythm prepares you to engage more meaningfully with each result, and the next section brings it all together.
The bottom line: what you need to know
Signatera gives you and your care team a powerful, personalized window into what’s happening at the cellular level, long before a scan could ever show it.
Here’s what the evidence adds up to:
- It’s built around your tumor. Signatera sequences your specific tumor’s DNA fingerprint and tracks those exact mutations in your blood. No two tests are alike, because no two cancers are alike.
- A positive result carries real weight. When MRD is detected, Signatera’s sensitivity and specificity data show greater than 90% sensitivity in predicting recurrence, often months ahead of imaging. That’s actionable information.
- A negative result is reassuring, not final. Lower ctDNA levels point to lower recurrence risk, but serial testing remains essential. A trend across multiple draws, not a single snapshot, is what gives your care team confidence.
- Results can open clinical doors. A positive ctDNA result may qualify you for trials like CIRCULATE-US, where treatment decisions are guided directly by liquid biopsy data rather than imaging alone.
ctDNA results are a starting point for decisions. Knowing how to read them, ask about them, and act on them puts you in a stronger position within your own personalized care plan. The next section walks you through exactly how to do that.
Taking control. Questions for your care team
Start with these specific questions at your next visit:
- “Does this result change my staging or monitoring plan?” A positive result for molecular residual disease (MRD) may prompt your care team to accelerate imaging, adjust your surveillance schedule, or revisit treatment options entirely.
- “Am I a candidate for ctDNA-guided clinical trials?” ctDNA-positive patients are increasingly being prioritized in emerging adjuvant and intervention trials, and your result could open doors that a standard scan would never unlock.
- “How often should we retest, and what would a trend in either direction mean for my personalized care plan?”
Being a proactive partner in your own care means showing up informed, asking the hard questions, and using every tool available to you. Your results are data. What you do with them, together with your care team, is where it matters most.
